1
NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma
Condition(s):Oesophageal Squamous Cell CarcinomaLast Updated:January 7, 2020Not yet recruiting
SHR-1316: 10 Clinical Trials
Hide Studies Not Open or Pending
2
A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients
Condition(s):Advanced Solid TumorsLast Updated:September 30, 2019Completed
3
Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors
Condition(s):TumorLast Updated:March 22, 2018Unknown status
4
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
Condition(s):Advanced MalignanciesLast Updated:February 19, 2020Recruiting
5
SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer
Condition(s):Advanced Esophageal Squamous Cell CancerLast Updated:November 6, 2018Recruiting
6
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Condition(s):Extensive-stage Small Cell Lung CancerLast Updated:October 18, 2018Not yet recruiting
7
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Condition(s):Non-Small-Cell Lung CancerLast Updated:March 20, 2020Not yet recruiting
8
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
Condition(s):Small Cell Lung CancerLast Updated:June 22, 2020Recruiting
9
A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients
Condition(s):Small Cell Lung CancerLast Updated:August 1, 2019Not yet recruiting
10
A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases.
Condition(s):Breast CancerLast Updated:March 11, 2020Not yet recruiting